MA33105B1 - Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase - Google Patents
Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestéraseInfo
- Publication number
- MA33105B1 MA33105B1 MA34150A MA34150A MA33105B1 MA 33105 B1 MA33105 B1 MA 33105B1 MA 34150 A MA34150 A MA 34150A MA 34150 A MA34150 A MA 34150A MA 33105 B1 MA33105 B1 MA 33105B1
- Authority
- MA
- Morocco
- Prior art keywords
- phenyl
- inhibitors
- phosphodiesterase
- pyridin
- benzoic acid
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title 2
- 239000005711 Benzoic acid Substances 0.000 title 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 235000010233 benzoic acid Nutrition 0.000 title 1
- 125000001495 ethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 title 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 1-PHENYL-2-PYRIDINYL Chemical class 0.000 abstract 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES INHIBITEURS DE L'ENZYME PHOSPHODIESTÉRASE 4 (PDE4). PLUS PARTICULIÈREMENT, L'INVENTION CONCERNE DES COMPOSÉS QUI SONT DÉRIVÉS D'ALCOOLS 1-PHÉNYL-2-PYRIDINYL ALKYLIQUES, DES PROCÉDÉS DE PRÉPARATION DESDITS COMPOSÉS, DES COMPOSITIONS LES COMPRENANT, LEURS COMBINAISONS ET LEURS UTILISATIONS THÉRAPEUTIQUES. DANS LA FORMULE (I), N REPRÉSENTE O OU 1; R1 ET R2 PEUVENT ÊTRE IDENTIQUES OU DIFFÉRENTS, ET SONT SÉLECTIONNÉS DANS LE GROUPE CONSTITUÉ PAR: - ALKYLE C1-C6 LINÉAIRE OU RAMIFIÉ; - OR3 OÙ R3 REPRÉSENTE ALKYLE C1-C6 ÉVENTUELLEMENT SUBSTITUÉ PAR UN OU PLUSIEURS GROUPES CYCLOALKYLES C3-C7; ET - HNSO2R4 OÙ R4 REPRÉSENTE ALKYLE C1-C4 ÉVENTUELLEMENT SUBSTITUÉ PAR UN OU PLUSIEURS ATOMES D'HALOGÈNE OU PAR UN GROUPE C1-C4, R1 ET/OU R2 REPRÉSENTANT HNSO2R4. LES AUTRES VARIABLES SONT TELLES QUE DÉFINIES DANS LES REVENDICATIONS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09001660A EP2216327A1 (fr) | 2009-02-06 | 2009-02-06 | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| PCT/EP2010/000676 WO2010089107A1 (fr) | 2009-02-06 | 2010-02-04 | Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33105B1 true MA33105B1 (fr) | 2012-03-01 |
Family
ID=40674203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34150A MA33105B1 (fr) | 2009-02-06 | 2010-02-04 | Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US8440834B2 (fr) |
| EP (2) | EP2216327A1 (fr) |
| JP (2) | JP5612610B2 (fr) |
| KR (1) | KR101337728B1 (fr) |
| CN (1) | CN102317262B (fr) |
| AR (1) | AR075243A1 (fr) |
| AU (1) | AU2010211274B2 (fr) |
| BR (1) | BRPI1005695A8 (fr) |
| CA (1) | CA2751494C (fr) |
| CL (1) | CL2011001876A1 (fr) |
| CO (1) | CO6400217A2 (fr) |
| CY (1) | CY1113764T1 (fr) |
| EA (1) | EA019113B1 (fr) |
| ES (1) | ES2395528T3 (fr) |
| GE (1) | GEP20135919B (fr) |
| HR (1) | HRP20121004T1 (fr) |
| IL (1) | IL214446A (fr) |
| JO (1) | JO2761B1 (fr) |
| MA (1) | MA33105B1 (fr) |
| ME (1) | ME02325B (fr) |
| MX (1) | MX2011007857A (fr) |
| MY (1) | MY152048A (fr) |
| NZ (1) | NZ594413A (fr) |
| PE (1) | PE20120055A1 (fr) |
| PL (1) | PL2393782T3 (fr) |
| PT (1) | PT2393782E (fr) |
| RS (1) | RS52605B (fr) |
| SG (1) | SG173208A1 (fr) |
| SI (1) | SI2393782T1 (fr) |
| TN (1) | TN2011000346A1 (fr) |
| TW (1) | TWI459945B (fr) |
| UA (1) | UA102574C2 (fr) |
| WO (1) | WO2010089107A1 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2022783A1 (fr) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase |
| EP2216327A1 (fr) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| CA2807406C (fr) | 2010-08-03 | 2018-12-11 | Chiesi Farmaceutici S.P.A. | Formulation pharmaceutique comprenant un inhibiteur de phosphodiesterase |
| SI2600830T1 (en) * | 2010-08-03 | 2018-05-31 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising a phosphodiesterase inhibitor |
| EP2718267B1 (fr) | 2011-06-06 | 2016-08-10 | Chiesi Farmaceutici S.p.A. | Dérivés d'alcools alkyl 1-phényl-2-pyridinyl en tant qu'inhibiteurs de phosphodiestérase |
| EP2760838B1 (fr) | 2011-09-26 | 2017-05-10 | Chiesi Farmaceutici S.p.A. | Dérivés de 1-phényl-2-pyridinyl alkyl alcool en tant qu'inhibiteurs du phosphodiestérase |
| CN103889972A (zh) * | 2011-10-21 | 2014-06-25 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 |
| AR089232A1 (es) * | 2011-12-16 | 2014-08-06 | Chiesi Farma Spa | Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia |
| IN2014DN10239A (fr) | 2012-06-04 | 2015-08-07 | Chiesi Farma Spa | |
| AR093796A1 (es) * | 2012-12-05 | 2015-06-24 | Chiesi Farm Spa | Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa |
| KR20150091061A (ko) | 2012-12-05 | 2015-08-07 | 키에시 파르마슈티시 엣스. 피. 에이. | Pde4-억제제로서 페닐에틸피리딘 유도체 |
| HK1212988A1 (zh) | 2012-12-05 | 2016-07-22 | 奇斯药制品公司 | 作为pde-4抑制剂的苯基乙基吡啶衍生物 |
| WO2014086852A1 (fr) | 2012-12-05 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Dérivés de phényléthylpyridine comme inhibiteurs de pde4 |
| US9427376B2 (en) | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| JP6458957B2 (ja) * | 2013-10-22 | 2019-01-30 | チエシ ファルマスティスィ エス．ピー．エー． | Ｐｄｅ４阻害剤の製造方法 |
| AR098621A1 (es) | 2013-12-05 | 2016-06-01 | Chiesi Farm Spa | Derivados de heteroarilo |
| HK1225384A1 (zh) | 2013-12-05 | 2017-09-08 | 奇斯药制品公司 | 用於治疗呼吸病的二苯甲基衍生物 |
| EP3152202B1 (fr) * | 2014-06-04 | 2018-11-28 | Chiesi Farmaceutici S.p.A. | Dérivés de 3,5-dichloro,4-(3,4-(cyclo-)alcoxyphényl)--2-carbonyloxy)éthyl)pyridine utilisés comme inhibiteurs de pde-4 et antagonistes des recepteures muscarinic m3 |
| EP3152203A1 (fr) * | 2014-06-04 | 2017-04-12 | Chiesi Farmaceutici S.p.A. | Dérivés de 3,5-dichloro,4-(3,4-(cyclo-)alcoxyphényl)-2-carbonyloxy)éthyl)pyridine utilisés comme inhibiteurs de pde-4 |
| US9326976B2 (en) | 2014-06-05 | 2016-05-03 | Chiesi Farmaceutici S.P.A. | Carbamate derivatives |
| US9763924B2 (en) * | 2014-06-05 | 2017-09-19 | Chiesi Farmaceutici S.P.A. | Aminoester derivatives |
| WO2017089347A1 (fr) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf |
| EP3487501A1 (fr) * | 2016-07-20 | 2019-05-29 | Allergan, Inc. | Méthodes, compositions et composés pour le traitement d'états pathologiques dermatologiques et oculaires |
| MA51413A (fr) * | 2017-12-28 | 2021-04-28 | Chiesi Farm Spa | Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique |
| US11813360B2 (en) | 2018-07-27 | 2023-11-14 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| CN115466169B (zh) * | 2021-06-10 | 2024-03-26 | 中国医学科学院药物研究所 | 取代邻苯二酚醚类化合物及其制备方法和应用 |
| WO2023117985A1 (fr) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Formulations de poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée |
| JP2025514863A (ja) | 2022-04-27 | 2025-05-09 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｐｄｅ４阻害剤の新規結晶形態 |
| WO2024027901A1 (fr) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 |
| EP4590273A1 (fr) | 2022-09-22 | 2025-07-30 | Chiesi Farmaceutici S.p.A. | Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4 |
| WO2024062006A1 (fr) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4 |
| CN119947705A (zh) | 2022-09-22 | 2025-05-06 | 奇斯药制品公司 | 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263495B (fr) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| PL178314B1 (pl) | 1993-07-02 | 2000-04-28 | Byk Gulden Lomberg Chem Fab | Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy |
| GB9412573D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| DE602007012105D1 (de) * | 2006-07-14 | 2011-03-03 | Chiesi Farma Spa | Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren |
| EP2022783A1 (fr) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase |
| EP2070913A1 (fr) | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'ester en tant qu'inhibiteurs de la phosphodiestérase |
| EP2110375A1 (fr) | 2008-04-14 | 2009-10-21 | CHIESI FARMACEUTICI S.p.A. | Inhibiteurs de la phosphodiestérase de type 4 appartenant à la classe tertiaire d'amine |
| EP2216327A1 (fr) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| SI2600830T1 (en) | 2010-08-03 | 2018-05-31 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising a phosphodiesterase inhibitor |
| CA2807406C (fr) | 2010-08-03 | 2018-12-11 | Chiesi Farmaceutici S.P.A. | Formulation pharmaceutique comprenant un inhibiteur de phosphodiesterase |
| EP2718267B1 (fr) | 2011-06-06 | 2016-08-10 | Chiesi Farmaceutici S.p.A. | Dérivés d'alcools alkyl 1-phényl-2-pyridinyl en tant qu'inhibiteurs de phosphodiestérase |
| EP2760838B1 (fr) | 2011-09-26 | 2017-05-10 | Chiesi Farmaceutici S.p.A. | Dérivés de 1-phényl-2-pyridinyl alkyl alcool en tant qu'inhibiteurs du phosphodiestérase |
| CN103889972A (zh) | 2011-10-21 | 2014-06-25 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 |
| IN2014DN10239A (fr) | 2012-06-04 | 2015-08-07 | Chiesi Farma Spa | |
| AR093796A1 (es) | 2012-12-05 | 2015-06-24 | Chiesi Farm Spa | Derivados del alcohol 1-fenil-2-piridinil alquilico como inhibidores de la fosfodiesterasa |
-
2009
- 2009-02-06 EP EP09001660A patent/EP2216327A1/fr not_active Withdrawn
-
2010
- 2010-02-03 JO JO201033A patent/JO2761B1/en active
- 2010-02-04 NZ NZ594413A patent/NZ594413A/xx unknown
- 2010-02-04 TW TW099103291A patent/TWI459945B/zh active
- 2010-02-04 EP EP10704746A patent/EP2393782B1/fr active Active
- 2010-02-04 RS RS20120547A patent/RS52605B/sr unknown
- 2010-02-04 MY MYPI2011003639 patent/MY152048A/en unknown
- 2010-02-04 MX MX2011007857A patent/MX2011007857A/es active IP Right Grant
- 2010-02-04 SI SI201030094T patent/SI2393782T1/sl unknown
- 2010-02-04 JP JP2011548600A patent/JP5612610B2/ja active Active
- 2010-02-04 SG SG2011056165A patent/SG173208A1/en unknown
- 2010-02-04 WO PCT/EP2010/000676 patent/WO2010089107A1/fr not_active Ceased
- 2010-02-04 ES ES10704746T patent/ES2395528T3/es active Active
- 2010-02-04 UA UAA201108827A patent/UA102574C2/ru unknown
- 2010-02-04 PE PE2011001441A patent/PE20120055A1/es active IP Right Grant
- 2010-02-04 PT PT107047466T patent/PT2393782E/pt unknown
- 2010-02-04 EA EA201190099A patent/EA019113B1/ru unknown
- 2010-02-04 CA CA2751494A patent/CA2751494C/fr active Active
- 2010-02-04 MA MA34150A patent/MA33105B1/fr unknown
- 2010-02-04 AU AU2010211274A patent/AU2010211274B2/en active Active
- 2010-02-04 PL PL10704746T patent/PL2393782T3/pl unknown
- 2010-02-04 GE GEAP201012324A patent/GEP20135919B/en unknown
- 2010-02-04 AR ARP100100311A patent/AR075243A1/es not_active Application Discontinuation
- 2010-02-04 CN CN201080006643.7A patent/CN102317262B/zh active Active
- 2010-02-04 KR KR1020117016842A patent/KR101337728B1/ko active Active
- 2010-02-04 BR BRPI1005695A patent/BRPI1005695A8/pt not_active Application Discontinuation
- 2010-02-04 ME MEP-2016-19A patent/ME02325B/me unknown
- 2010-02-04 HR HRP20121004AT patent/HRP20121004T1/hr unknown
- 2010-02-05 US US12/700,926 patent/US8440834B2/en active Active
-
2011
- 2011-07-13 TN TN2011000346A patent/TN2011000346A1/fr unknown
- 2011-08-04 CO CO11098671A patent/CO6400217A2/es not_active Application Discontinuation
- 2011-08-04 IL IL214446A patent/IL214446A/en active IP Right Grant
- 2011-08-04 CL CL2011001876A patent/CL2011001876A1/es unknown
-
2012
- 2012-09-14 US US13/618,346 patent/US20130012487A1/en not_active Abandoned
- 2012-12-04 CY CY20121101183T patent/CY1113764T1/el unknown
-
2013
- 2013-06-28 US US13/930,304 patent/US8648204B2/en active Active
- 2013-12-17 US US14/108,731 patent/US8859778B2/en active Active
-
2014
- 2014-09-04 JP JP2014179895A patent/JP2015038079A/ja active Pending
- 2014-09-10 US US14/482,287 patent/US9056176B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33105B1 (fr) | Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase | |
| MA31919B1 (fr) | Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif | |
| MA29909B1 (fr) | Derives de pyridazine | |
| MA32150B1 (fr) | Inhibiteurs heterocycliques de la stearoyl-coa desaturase | |
| CL2022002919A1 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA33768B1 (fr) | Triazolopyridines | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA34359B1 (fr) | Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique | |
| MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
| MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA27559A1 (fr) | Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA31763B1 (fr) | Inhibiteurs de kinase de type polo | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
| MA35012B1 (fr) | Composition phytosanitaire comprenant des huiles essentielles renforçant l'activité anti-fongique | |
| MA29775B1 (fr) | Derives de pyrazolone | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| MA37798B1 (fr) | 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes | |
| EP4249070A3 (fr) | Dérivés hétéroaryle bicycliques utilisés en tant qu'inhibiteurs de l'ectonucléotide pyrophosphatase/phosphodiestérase 1 | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA32929B1 (fr) | Lactames en tant qu'inhibiteurs de bêta-sécrétase | |
| MA43960A (fr) | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 | |
| MA34917B1 (fr) | Dérivés substitués de l'acide 3-hétéroaroylamino-propionique et leur utilisation comme composés pharmaceutiques |